Pharmacological preconditioning. Focus on nicorandil

DOI: https://doi.org/10.29296/25877305-2018-08-20
Download full text PDF
Issue: 
8
Year: 
2018

R. Gostishchev(1); G. Soboleva(1), MD; Professor A. Samko(1), MD; Professor A. Osiev(2), MD 1-National Research Medical Center of Cardiology, Ministry of Health of Russia, Moscow 2-M.F. Vladimirsky Moscow Regional Clinical Research Institute, Moscow

The paper discusses the mechanism of action, the efficacy and safety of the ATP-dependent potassium channel activator nicorandil in myocardial pharmacological preconditioning. It gives the data of clinical trials confirming the possibility of reducing the risk of periprocedural myocardial damage when this drug is administered for prevention purposes. There are data on the positive effect of nicorandil on myocardial contractility and clinical outcomes.

Keywords: 
cardiology
myocardial pharmacological preconditioning
nicorandil
ATP-dependent potassium channel activator
percutaneous coronary interventions
cardiac enzymes



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Rubrikator klinicheskih rekomendatsij i svjazannyh dokumentov [Elektronnyj resurs]. Rossijskoe kardiologicheskoe obschestvo; Natsional'noe obschestvo po izucheniju ateroskleroza; Natsional'noe obschestvo po aterotrombozu – Elektron. dan. M.: Klinicheskie rekomendatsii. Stabil'naja ishemicheskaja bolezn' serdtsa Rezhim dostupa: http://cr.rosminzdrav.ru/schema.html?id=133#/text.
  2. Fraker T. Jr, Fihn S. 2002 Chronic stable Angina Writing Committee, American College of Cardiology, American Heart Association. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina // J. Am. Coll. Cardiol. – 2007; 50 (23): 2264–746.
  3. Fox K., Garcia M., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of stable Angina Pectoris of the European society of Cardiology // Eur. Heart J. – 2006; 27 (11): 1341–81.
  4. Horinaka S. Use of Nicorandil in Cardiovascular Disease and Its Optimization // Drugs. – 2011; 71 (9): 1105.
  5. Bokerija L.A., Alekjan B.G. Sostojanie rentgenendovaskuljarnoj diagnostiki i lechenija zabolevanij serdtsa i sosudov v Rossijskoj Federatsii (2015 g) // Endovaskuljarnaja hirurgija. – 2016; 3 (2): 5–21.
  6. Murry C., Jenning R., Reimer K. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium // Circulation. – 1986; 74 (5): 1122–36.
  7. Turer A., Hill J. Pathogenesis of myocardial ischemia–reperfusion injury and rationale for therapy // Am. J. Cardiol. – 2010; 106: 360–8.
  8. Kharbanda R. Cardiac conditioning: a review of evolving strategies to reduce ischemia–reperfusion injury // Heart. – 2010; 96: 1179–86.
  9. Hausenloy D., Yellon D. Preconditioning and postconditioning: underlying and clinical application // Atherosclerosis. – 2009; 204 (2): 334–41.
  10. Lupanov V.P., Maksimenko A.V. Protektivnaja ishemija v kardiologii. Formy konditsionirovanija miokarda // Kardiovask. ter. i profilakt. – 2011; 10 (1): 96–103.
  11. Hausenloy D., Ong S., Yellon D. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning // Basic Res. Cardiol. – 2009; 104 (2): 189–202.
  12. Bojtsov S.A. Patogenez hronicheskoj formy ishemicheskoj bolezni serdtsa. V kn. «Rukovodstvo po aterosklerozu i ishemicheskoj bolezni serdtsa». Pod red. E.I. Chazova / M.: Media Medika, 2007; 330–48.
  13. Lomivorotov V.V., Ponomarev D.N., Shmyrev V. A. i dr. Primenenie distantsionnogo ishemicheskogo prekonditsionirovanija u kardiohirurgicheskih bol'nyh // Obschaja reanimatologija. – 2011; 7 (3): 63–9.
  14. Przyklenk K., Bauer B., Ovize M. et al. Regional ischemic «preconditioning» protects remote virgin myocardium from subsequent sustained coronary occlusion // Circulation. – 1993; 87 (3): 893–9.
  15. Sergienko V.I., Petrosjan E.A., Onopriev V.I. i dr. Morfologicheskie izmenenija legkih pri modelirovanii i lechenii ishemicheskih i reperfuzionnyh povrezhdenij konechnosti // Obschaja reanimatologija. – 2006; II (5–6): 129–32.
  16. Miura T., Tanno M., Sato T. Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion induced necrosis // Cardiovasc. Res. – 2010; 88 (1): 7–15.
  17. Yang X., Cohen M., Downey J. Mechanism of cardioprotection by early ischemic preconditioning // Cardiovasc. Drugs Ther. – 2010; 24 (3): 225–34.
  18. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators // Am. J. Cardiol. – 1989; 63 (21): 18–24.
  19. Malysheva A.M., Martsevich S.Ju., Ginzburg M.L. Primenenie nikorandila — preparata s dopolnitel'nymi kardioprotektivnymi svojstvami u patsientov s ishemicheskoj bolezn'ju serdtsa // Ter. arh. – 2011; 83 (9): 14–9.
  20. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil // Cardiovasc. Drugs Ther. – 1990; 4 (4): 1075–88.
  21. IONA study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial // Lancet. – 2002; 359 (9314): 1269–75.
  22. Horinaka S., Yabe A., Yagi H. et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study // Circ. J. – 2010; 74: 503–9.
  23. Martsevich S.Ju., Kutishenko N.P., Deev A.D. Sravnitel'naja otsenka antianginal'noj effektivnosti i bezopasnosti preparata nikorandil na fone bazisnoj terapii β-adrenoblokatorami u bol'nyh ishemicheskoj bolezn'ju serdtsa so stabil'noj stenokardiej // Kardiologija. – 2016; 10: 30–4.
  24. Voronina V.P. Martsevich S.Ju. i dr. Otsenka antiishemicheskogo i antianginal'nogo effektov nikorandila s pomosch'ju nagruzochnyh testov na tredmile (KVAZAR) // RKZh. – 2017; 3: 97–103.
  25. Ishii H., Ichimiya S., Kanashiro M. et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction // Circulation. – 2005; 112 (9): 1284–8.
  26. Ono H., Osanai T., Ishizaka H. et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation // Am. Heart J. – 2004; 148 (4): E15.
  27. Ota S., Nishikawa H., Takeuchi M. et al. Impact of Nicorandil to Prevent Reperfusion Injury in Patients With Acute Myocardial Infarction sigmart Multicenter Angioplasty Revascularization trial (SMART) // Circ. J. – 2006; 70: 1099–104.
  28. Lee H., An S., Choi J. et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction // Circ. J. – 2008; 72 (9): 1425–9.
  29. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nucl. Med. – 2007; 48: 1676–82.
  30. Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. – 2012; 59 (1): 14–21. DOI: 10.1016/j.jjcc.2011.08.001.
  31. Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anatolian J. Cardiol. – 2015; 15: 125–31.
  32. Izumiya Y., Kojima S., Kojima S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214: 415–21.
  33. Kawai Y., Hisamatsu K., Matsubara H. et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon // Eur. Heart J. – 2009; 30 (7): 765–72. DOI: 10.1093/eurheartj/ehp077.
  34. Isono T., Kamihata H., Sutani Y. et al. Nicorandil suppressed myocardial injury after percutaneous coronary intervention // Int. J. Cardiol. – 2008; 123 (2): 123–8.
  35. Hirohata A., Yamamoto K., Hirose E. et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study // EuroIntervention. – 2014; 9 (9): 1050–6. DOI: 10.4244/EIJV9I9A178.
  36. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European society of Cardiology // Eur. Heart J. – 2013; 34 (38): 2949–3003. DOI: 10.1093/eurheartj/eht296.
  37. Giljarevskij S.R., Rezvan V.V., Kuz'mina I.M. i dr. Sovremennye podhody k protivoishemicheskoj terapii bol'nyh so stabil'nym techeniem ishemicheskoj bolezni serdtsa // Med. alfavit. Kardiologija. 21 (211): 15–20